Ratings Braskem S.A.

Equities

BRKM5

BRBRKMACNPA4

Delayed Sao Paulo 12:11:43 2024-03-28 pm EDT 5-day change 1st Jan Change
26.53 BRL +21.14% Intraday chart for Braskem S.A. -1.12% +21.36%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • With regards to fundamentals, the enterprise value to sales ratio is at 0.76 for the current period. Therefore, the company is undervalued.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.

Weaknesses

  • The company has insufficient levels of profitability.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company appears highly valued given the size of its balance sheet.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Commodity Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
+21.36% 4.32B
C+
+9.48% 109B
A-
-6.47% 61.6B
A-
+4.73% 34.64B
B
+8.03% 33.41B
A-
+10.95% 31.17B
B
+9.13% 19.53B
B-
+9.93% 18.93B
B+
+6.09% 15.7B
C+
+4.83% 14.64B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes